Black Diamond Therapeutics, Inc. (BDTX) key performance indicators and operating metrics (8 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Central Nervous System Objective Response Rate (Response Assessment in Neuro-Oncology for Brain Metastases) | 86.00 percent | FY2026-Q2 |
| Disease Control Rate (Response Evaluation Criteria in Solid Tumors 1.1) | 91.00 percent | FY2026-Q2 |
| Patients Remaining on Therapy | 23.00 | FY2026-Q2 |
| Non-Small Cell Lung Cancer Patients With Brain Metastases | 19.00 | FY2026-Q2 |
| Non-Small Cell Lung Cancer Patients With Measurable Central Nervous System Target Lesions | 7.00 | FY2026-Q2 |
| Objective Response Rate (Response-Evaluable Patients) | 60.00 percent | FY2025-Q4 |
| Confirmed Partial Response Patients | 25.00 | FY2025-Q3 |
| Frontline Non-Small Cell Lung Cancer Phase 2 Patients Enrolled | 43.00 | FY2025-Q3 |
Back to BDTX overview · BDTX earnings · BDTX holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.